Management of small cell lung cancer: recent developments for optimal care. Drugs. 2012;72(4):471–90. :10.2165/11597640-000000000-00000. .Raffaele Califano, Aidalena Z. Abidin, Rahul Peck, Corinne Faivre-Finn, Paul Lorigan. (2012) Management of Small Cell Lung Cancer : Recent Developments ...
Simon GR, Turrisi A. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:324S-339S.Simon GR,Turrisi A.Management of small cell lung cancer:ACCPevidence-based clinical practice guidelines(2nd edition). Chest . 2007...
The standard treatment of limited-stage small cell lung cancer (SCLC) isconcurrent cisplatin and etoposide with thoracic radiation therapy, whereas treatment of extensive-stage disease is typically chemotherapy alone with a platinum compound plus etoposide. Surgical resection of early disease is generally...
Surgical management of non-small cell lung cancer. In: Pearson F, editor. Pearson's Thoracic and Esophageal Surgery, 3rd ed. Philadelphia: Churchill Livingstone; 2008, p.765-80.GA KBaP (2008) Surgical management of non-small cell lung cancer. Pearson's Thoracic & Esophageal Surgery. ...
在过去的二十年中,围绕非小细胞肺癌(non-small cell lung cancer, NSCLC)的治疗多次取得突破,提升了人们对该疾病的生物学基础、肿瘤发生的机制、早期诊断和多方疗法的理解。虽说酪氨酸激酶(Tyrosine kinase,TK)小分子抑制剂和免疫疗法...
Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past two decades, increasing our understanding of the disease biology and mechanisms of tumour progression, and advancing early detection and multimodal care. The use of small molecule tyrosine ...
Lung cancerImmune checkpoint inhibitorsTargeted therapyThe past decade has seen a revolution of new advances in the management of non-small cell lung cancer (NSCLC) with remarkable progresses in screening, diagnosis, and treatment. The advances in systemic treatment have been driven primarily by the ...
Management of Advanced Non–Small Cell Lung Cancerdoi:10.1016/B978-0-323-48565-4.00006-0Bing XiaRoy S. HerbstLung Cancer: A Practical Approach to Evidence-Based Clinical Evaluation and Management
Lung cancer, and its most prevalent variant-non-small cell lung cancer (NSCLC)-is responsible for 85% of all lung cancer cases 1 and is a significant cause of death in the world, as well as in Brazil. It is estimated that, in 2012, approximately 1.6 million deaths occurred due to NSCL...
J. Combinatorial action of microRNAs let-7 and miR-34 effectively synergizes with erlotinib to suppress non-small cell lung cancer cell proliferation. Cell Cycle 14, 2171–2180 (2015). CAS PubMed PubMed Central Google Scholar Cortez, M. A. et al. Therapeutic delivery of miR-200c enhances...